Therapeutic Solutions International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSOI research report →
Price Chart
About the company
Therapeutic Solutions International, Inc. is dedicated to modulating the immune system to address a diverse array of serious conditions. The company formulates immune-modulatory agents targeting cancers, schizophrenia, suicidal ideation, and various neurological disorders like traumatic brain injury and chronic traumatic encephalopathy, alongside lung pathologies and general health maintenance.
- CEO
- Timothy George Dixon
- IPO
- 2008
- Employees
- 3
- HQ
- Elk City, ID, US
Get TickerSpark's AI analysis on TSOI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.23K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.52
- P/B
- 0.03
- EV/EBITDA
- -0.61
- Div Yield
- 0.00%
- Gross Margin
- 62.86%
- Op Margin
- -2006.67%
- Net Margin
- -2191.86%
- ROE
- -184.90%
- ROIC
- -91.55%
Latest fiscal year · YoY change
- Revenue
- $98.99K-52.1%
- Gross Profit
- $62.23K-51.1%
- Op Income
- $-1,986,479
- Net Income
- $-2,169,814+43.1%
- EPS
- $-0.00+53.3%
- OCF Growth
- -3.6%
- FCF Growth
- -5.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.24
- RSI (14)
- 48
- Avg Volume
- 4.26K
No earnings-call transcripts are available for TSOI yet.
- Free Float
- 89.1%
- Shares Outstanding
- 5.12B
- Float Shares
- 4.56B
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 24 | DIXON TIMOTHY G | other | 55,555,555 |
| Sep 30, 24 | Ichim Thomas | other | 10,000,000 |
| Jul 11, 24 | Ichim Thomas | other | 10,000,000 |
| Jul 11, 24 | DIXON TIMOTHY G | other | 20,000,000 |
| Jul 8, 24 | Ichim Thomas | other | 10,000,000 |
| Jul 8, 24 | DIXON TIMOTHY G | other | 25,000,000 |
| May 30, 24 | Ichim Thomas | other | 10,000,000 |
| May 30, 24 | DIXON TIMOTHY G | other | 37,500,000 |
| Apr 18, 24 | DIXON TIMOTHY G | other | 42,857,142 |
| Apr 18, 24 | Ichim Thomas | other | 15,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TSOI coverage
Recent articles, reports, and earnings notes.
No research on TSOI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TSOI report →Therapeutic Solutions International to Voluntarily Delist
businesswire.com · Apr 23
Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
businesswire.com · May 16
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
businesswire.com · Mar 4
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
businesswire.com · Feb 29
Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation
businesswire.com · Feb 26
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
businesswire.com · Jan 22
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™
businesswire.com · Jan 3
Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease
businesswire.com · Dec 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.